Market News

0 0 0

Source: Seeking Alpha News Agency

1 month ago

Stock Medium Importance

PepsiCo: Where Is The Sense Of Urgency?

PepsiCo is underperforming the consumer staples sector, hindered by weak North American volumes and slower growth versus Coca-Cola. I rate PEP a Hold, citing fair valuation, a 4.3% dividend yield, but a lack of near-term growth catalysts or innovation-driven inflection. International segments, especially IB Franchise and Asia Pacific Foods, remain bright spots with high-single digit organic growth, but domestic food volumes are a persistent drag.

Related Symbols 1

P PEP PEP

Source: Seeking Alpha

0 0 0

Source: PRNewsWire News Agency

1 month ago

Stock Medium Importance

Avient Announces Second Quarter 2026 Results; Increases Full-Year Guidance

Second quarter sales grew 5.8% to $917 million, driven by 4.3% organic sales growth and 1.5% favorable foreign exchange, with organic growth in both business segments Second quarter GAAP EPS of $0.70 compared to $0.57 in the prior year quarter Second quarter adjusted EPS grew 20% over the prior year to $0.96; exceeded adjusted EPS guidance of $0.89, primarily driven by better-than-expected organic volume growth Strong cash flow generation in the quarter supported $50 million of debt repayment; expect to repay a total of $100 to $150 million during the full year 2026 Increasing 2026 full year adjusted EPS guidance range to $3.10 to $3.25 from previous guidance of $2.93 to $3.17; updated full year adjusted EPS guidance range represents 10% to 15% growth over the prior year CLEVELAND, Aug. 6, 2026 /PRNewswire/ -- Avient Corporation (NYSE: AVNT), an innovator of materials solutions, today announced its second quarter results for 2026. Second quarter GAAP earnings per share (EPS) were $0.70 compared to $0.57 in the prior year quarter.

Related Symbols 1

A AVNT AVNT

Source: PRNewsWire

0 0 0

Source: Seeking Alpha News Agency

1 month ago

Stock Medium Importance

Sanofi: How I Leveraged This Undervalued Dividend Aristocrat

Sanofi is rated a Buy, with ~33.5% upside to €99.5 fair value (or $57 for SNY ADRs), resulting from averaging optimistic with pessimistic scenarios. Dupixent remains Sanofi's key growth driver, with a €25B 2030 sales target, but faces biosimilar risk post-2031 and a significant lawsuit threat. New pharma launches and pipeline assets are expected to offset legacy declines, targeting €10B in 2030 sales and with possible margin expansion toward 40%.

Related Symbols 1

S SNY SNY

Source: Seeking Alpha

0 0 0

Source: The Guardian News Agency

1 month ago

Stock Medium Importance

‘Mama mia!': Trump tariffs refund ignites 53% profit spike at Nintendo

Quarterly profit jump fuelled largely by unknown US refund amount as Japanese video game giant records overall sales drop

Related Symbols 1

N NTDOY NTDOY

Source: The Guardian

0 0 0

Source: 24/7 Wall Street News Agency

1 month ago

Stock Medium Importance

Elon Musk Loses $87 Billion In A Single Day As SpaceX Stock Craters After Earnings

Elon Musk lost roughly $87 billion in a single trading session on Wednesday, Aug.

Related Symbols 1

S SPCX SPCX

Source: 24/7 Wall Street

0 0 0

Source: Invezz News Agency

1 month ago

Stock Medium Importance

Why Nvidia, Micron, AMD stocks are down pre-market after SanDisk shock

Nvidia, Micron and AMD slipped in US pre-market trading on Thursday after SanDisk's outlook triggered a retreat across artificial-intelligence and memory-chip shares. At 5.30am ET, Nvidia was slightly lower, Micron had fallen 3.3% and AMD was down 1.9%, while SanDisk tumbled more than 9%.

Related Symbols 1

A AMD AMD

Source: Invezz

0 0 0

Source: Forbes News Agency

1 month ago

Stock Medium Importance

Oscar Health Reports Another Big Profit As Obamacare Member Costs Ease

Health insurer Oscar Health swung to a $361 million second quarter profit while eclipsing $1 billion in net income for the first six months of the year as health plan membership rose and medical costs eased.

Related Symbols 1

O OSCR OSCR

Source: Forbes

0 0 0

Source: Proactive Investors News Agency

1 month ago

Stock Medium Importance

Hikma jumps 10% as brokers point to profit beat and undemanding rating

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after first-half results came in ahead of expectations on profits, with both Peel Hunt and Stifel keeping buy ratings. The scale of the beat is the story.

Related Symbols 1

H HKMPF HKMPF

Source: Proactive Investors

0 0 0

Source: CNBC News Agency

1 month ago

Stock Medium Importance

AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

Reported talks of a tie-up between two industry giants could deliver instant U.S. scale for AstraZeneca through Bristol Myers Squibb's U.S.-centric business, but at the cost of slower growth and integration risk. The reports had the industry thinking about a kind of dealmaking it has avoided for more than a decade.

Related Symbols 1

A AZN AZN

Source: CNBC

0 0 0

Source: Seeking Alpha News Agency

1 month ago

Stock Medium Importance

Array Technologies, Inc. (ARRY) Q2 2026 Earnings Call Transcript

Related Symbols 1

A ARRY ARRY

Source: Seeking Alpha

0 0 0

Source: Seeking Alpha News Agency

1 month ago

Stock Medium Importance

Chipotle: One Good Quarter Doesn't Reset The Risk Profile

Chipotle delivered a Q2 beat with comp sales rebounding to 2.2% growth, driven by new menu items and a revamped rewards program. Despite revenue and comp growth, CMG's net income and EPS declined due to rising food and labor costs, compressing restaurant-level margins. I maintain a "Sell" rating, citing unsustainable valuation at over 20x P/E and ongoing EPS compression despite recent operational improvements.

Related Symbols 1

C CMG CMG

Source: Seeking Alpha

0 0 0